

# Zynerba Pharmaceuticals

12:50 11 Jun 2019

## Zynerba wins new US patent for treatment of Autism Spectrum Disorder with CBD

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) revealed Tuesday that the US Patent and Trademark Office granted the company a new patent for treating Autism Spectrum Disorder, characterized by challenges with social skills and speech, with cannabidiol (CBD).

The company said it received US Patent No 10,314,792, titled "Treatment of Autism Spectrum Disorder with Cannabidiol," which includes claims linked to methods of treating Autism Spectrum Disorder by administering a therapeutically effective amount of synthetic CBD.

The new patent, which expires in 2038, is part of an expanding intellectual property portfolio covering the Devon, Pennsylvania-based company's Zygel, a CBD gel.

Zygel was earlier referred to as ZYN002, a synthetic cannabidiol formulated as a permeation-enhanced gel for skin delivery.

**READ:** Zynerba Pharmaceuticals scores Fast Track FDA designation for Zygel CBD gel

The new patent arrives as enrollment speeds up in Zynerba's open label Phase 2 BRIGHT study evaluating the safety, tolerability and potency of Zygel for treating children and adolescents with Autism Spectrum Disorder. The company expects to report top line data in the first half of 2020.

Zynerba already has a patent (No 10,213,390) for claims linked to methods of treating Fragile X Syndrome by administering an effective dose of synthetic or purified CBD.

The US Food and Drug Administration earlier granted fast track designation to Zygel to expedite the development of the drug to treat Fragile X syndrome in children and young adults suffering from this common form of inherited learning disability and attention deficit disorder.

Enrollment is progressing in a pivotal CONNECT-FX Trial of Zygel in Fragile X syndrome, the company said in a statement with "data expected in the second half of 2019."

Contact Uttara Choudhury at [uttara@proactiveinvestors.com](mailto:uttara@proactiveinvestors.com)


Follow her on Twitter: [@UttaraProactive](https://twitter.com/UttaraProactive)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private

**Price:** 5.71

**Market Cap:** \$132.46 m

### 1 Year Share Price Graph



December 2018 June 2019 December 20

### Share Information

**Code:** ZYNE

**Listing:** NASDAQ

52 week	High	Low
	16.46	2.82

**Sector:** Pharma & Biotech

**Website:** [zynerba.com](http://zynerba.com)

### Company Synopsis:

*At Zynerba Pharmaceuticals, our team is dedicated to developing next-generation transdermally-delivered cannabinoid therapeutics for patients affected by rare and near-rare neuropsychiatric conditions. Often, these diseases have few, if any, treatment options and can leave patients and their families feeling helpless and alone.*

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Zynerba Pharmaceuticals named herein, including the promotion by the Company of Zynerba Pharmaceuticals in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).